ACCC association of cancer care centers

FDA Approves Revumenib for Relapsed or Refractory Acute Leukemia With a KMT2A Translocation

FDA Approves Revumenib for Relapsed or Refractory Acute Leukemia With a KMT2A Translocation

Posted on 11/20/2024

On November 15, the US Food and Drug Administration (FDA) approved revumenib, a menin inhibitor, for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene translocation in adult and pediatric patients 1 year and older.

For more information, read the FDA announcement and the Syndax Pharmaceuticals press release.

Related Content

FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma

May 12, 2026

FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer

May 8, 2026

FDA Approves Relacorilant With Nab-paclitaxel for Platinum-resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

March 26, 2026

FDA Approves Nivolumab With Chemotherapy for Previously Untreated Hodgkin Lymphoma

March 26, 2026

FDA Approves Teclistamab in Combination With Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma

March 6, 2026

FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-squamous Non-small Cell Lung Cancer

March 4, 2026

FDA Grants Traditional Approval to Encorafenib for Metastatic Colorectal Cancer With a BRAF V600E Mutation

March 4, 2026

FDA Approves Acalabrutinib With Venetoclax for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

February 20, 2026

Upcoming Events

ACCC Oncology Reimbursement Meeting | Providence

ACCC Oncology Reimbursement Meeting | Providence

In Person November 10, 2026 at 8:00 AM EST5 Avenue of the Arts, Providence, RI, USARenaissance Providence Downtown Hotel,
Register Now!